glp 1 semaglutida Health Canada warns about fake or unauthorized versions of GLP-1 drugs PDB-101: Diabetes Mellitus: Diabetes Mellitus:
Description
Career Burnout: Professionals need assurance about treatment fitting their packed schedules
The difference is the magnitude of weight loss, not the quality of it
This 72-week study enrolled adults with obesity or overweight plus weight-related health concerns (but not diabetes) and randomized them equally to tirzepatide (10 or 15 mg weekly) or semaglutide (1.7 or 2.4 mg weekly)
The medications do not affect how quickly patients wake from anaesthesia or increase the risk of anaesthetic awareness
The result is a combination of improved glycemic control and reduced caloric intake
